Prolife Concludes CPHI Milan 2026: Clinically Validated Cardiovascular Monitoring for International Markets
The team presented Prolife PX7 Premium and the Swiss brand’s approach to cardiovascular monitoring at home: blood pressure and atrial fibrillation in a single measurement.
The meetings in Milan focused on the growing role of home screening within consumer healthcare portfolios and the requirements for bringing clinically validated medical devices to new markets.
Blood Pressure and Atrial Fibrillation in One Measurement
Hypertension and atrial fibrillation are two leading risk factors for stroke. Prolife brings both into a single blood pressure measurement.
Prolife PX7 Premium combines blood pressure measurement and atrial fibrillation screening in one intelligent measurement process. The device is designed for regular home monitoring and supported by Prolife technologies developed around clinical relevance, accuracy and individual adaptation.
Prolife PX7 Premium: AFibra™ SMART and AIm Technologies
AFibra™ SMART technology detects atrial fibrillation during cuff inflation — automatically, with no additional action from the user. About 40% of people with AF show no symptoms. Regular home measurement with AFibra™ SMART gives every person a chance to act before a silent condition becomes a clinical event.
AFibra™ SMART serves as a screening aid and does not replace an ECG or diagnosis by a healthcare professional.
AIm (Artificial Intelligence measurement) technology makes every Prolife reading individual. The measurement process adapts to the individual — to their body, their physiology and their condition. The result is accuracy and comfort that feel personal, whoever is measuring and whenever they measure.
The blood pressure measurement accuracy of PX7 Premium has been clinically validated according to the AAMI/ESH/ISO Universal Standard ISO 81060-2:2018, including AMD1:2020 and AMD2:2024. The device is listed by STRIDE BP as a Preferred Device and features a validated cuff range of 22–45 cm.
Meetings with Distribution Partners at CPHI Milan 2026
CPHI Milan created a focused setting for conversations about clinical evidence, regulatory readiness and the future of home cardiovascular monitoring.
The Prolife team met current and prospective partners from the pharmaceutical, pharmacy and consumer health sectors. The discussions covered international market development, portfolio expansion and the role of clinically validated technologies in professional recommendation pathways.
For partners, Prolife PX7 Premium arrives market-ready: clinical validation, regulatory compliance and marketing support are already in place, and Prolife accompanies the partner from contract to first sales.
Distribution partners interested in bringing PX7 Premium to their markets can contact us.
We measure differently.